Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    Scorr-Insert
    X

    Find Psychiatry/Psychology Drugs in Phase II Clinical Development in UNITED KINGDOM

    A collaboration with SCORR Marketing

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Compass Pathways

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED KINGDOM United Kingdom

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              ISPE Manufacturing

              Participation Not Confirmed

              Update your events

              Compass Raises $80M to Take Magic Mushroom Drug Toward Phase 3

              Contact the Supplier

              Lead Product(s): Psilocybine

              Therapeutic Area: Psychiatry/Psychology

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: ATAI Life Sciences

              Deal Size: $80.0 million Upfront Cash: Undisclosed

              Deal Type: Series B Financing April 27, 2020

              Details:

              The raised capital will help advancing the world's first large-scale psilocybin therapy clinical trial, performed by COMPASS, in 20 sites across nine countries in Europe and North America.

              Compass Pathways

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED KINGDOM United Kingdom

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              ISPE Manufacturing

              Participation Not Confirmed

              Update your events

              COMPASS Pathways Granted Patent Covering Use of Its Psilocybin Formulation in Addressing Treatment-resistant Depression

              Contact the Supplier

              Lead Product(s): Psilocybine

              Therapeutic Area: Psychiatry/Psychology

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 13, 2020

              Details:

              Last month, COMPASS reported that COMP360 was well tolerated when administered to healthy adult volunteers with support from specially trained therapists in a randomised placebo-controlled trial.

              PharmaCompass__DigitalAd